Post-Market Surveillance Requirements for Medical Devices in Ethiopia

1. Key takeaways

Ethiopia treats post-market surveillance (PMS) as part of the registration chain rather than an optional activity. Manufacturers must establish a PMS system proportionate to the risk class of the device, and the PMS plan must be included in the registration technical documentation. Sterile devices, devices with a measuring function, and all Class III/C and above devices must submit vigilance and post-market surveillance reports at re-registration; high-risk products of the same category must also submit evidence of safety and performance to EFDA within one year of placing on the market. PMS therefore runs through three nodes: registration, the first year after market entry, and the year-5 re-registration. Each node has its own deliverable, its own audience inside the authority and its own documentary format, and a company that plans only for the re-registration node will discover the first-year obligation after the deadline has already started to run. The proportionality principle runs through all three nodes as well: the same risk class that shaped the clinical evidence at registration also calibrates how much post-market effort is considered adequate two and five years later.

2. Legal basis

3. Expert insights

Insight 1: proportionality is the design principle of PMS and also the yardstick applied during review.

The proportionality principle established by Article 19(1) matches the wording of Section 7.2, which requires a system proportionate to the risk class. The practical meaning is that a Class I device does not need the active follow-up and data collection intensity of a Class III device, but it cannot have no system at all; conversely, a high-risk device that relies only on passive complaint collection will be judged insufficient in intensity. Companies should therefore be able to explain, product by product, why the chosen surveillance intensity corresponds to the risk class recorded in the registration file.

Insight 2: because the PMS plan enters the registration technical documentation, it is already examined at the review stage.

Positioning the PMS plan as something to be added after approval is the wrong approach: it is part of the registration dossier and is reviewed during the technical assessment. A dossier that lacks the PMS plan creates a deviation from the structural requirements of EFDA/GDL/097 Version 002, and reviewers increasingly treat the plan as an indicator of whether the manufacturer has understood the Ethiopian system as a lifecycle regime rather than a one-off approval.

Insight 3: the reporting obligation is triggered by product attributes, not only by classification.

The trigger scope of item 12.1(h) covers sterile devices, devices with a measuring function, and all Class III/C and above devices. Note that the first two are attributes rather than classes: a Class II sterile device falls into the scope as well. Companies that screen only by the phrase Class III and above will miss sterile and measuring products, and the omission typically surfaces at re-registration when the missing reports are requested.

Insight 4: year 5 is not the only node; there is already one in year 1.

Item 9.2.3(e) requires evidence of safety and performance for Class III and above devices and Class C and above IVDs to be submitted within one year of placing on the market in Ethiopia, and the commitment must be written into the agency agreement. This is the submission most often missed when companies schedule their post-market calendar, because it arrives twelve months after approval, when project teams have usually moved on to other launches.

Insight 5: PMS data is the foundation of the trend report.

The trend report under the vigilance system requires a determination of whether similar events are increasing abnormally, and its precondition is exactly the routine accumulation of PMS data. Without a continuously operating PMS, trend reports can only be assembled after the fact; they then fail to trigger on time and cannot support the re-registration file either. Data architecture decisions made today therefore determine vigilance performance three years later.

4. Practical recommendations

1. Design PMS in layers by risk class: define the combination and frequency of active collection (follow-up, registry studies, literature monitoring) and passive collection (complaints, service records) for each class.
2. Write the PMS plan into the registration dossier, aligned with the chapter structure of EFDA/GDL/097 Version 002.
3. Screen reporting obligations on two dimensions, attribute plus class: first check the sterile and measuring attributes, then check Class III/C and above.
4. Set two calendar nodes: submit the safety and performance evidence one year after market entry, and file the re-registration package with the PMS report when the window opens 3 months before expiry.
5. Unify the data schema: use one set of codes and fields for complaints, events, service records and recalls, so that trend determination is possible.
6. Share data with the local representative: PMS execution often depends on first-line information on the representative side, so agree a data return frequency.

5. Verification checklist

• □ Proportionate PMS system established by risk class
• □ PMS plan included in the registration technical documentation
• □ Reporting obligations screened on the three dimensions: sterile, measuring, Class III and above
• □ One-year evidence submission node scheduled
• □ Year-5 re-registration PMS report node scheduled
• □ Data schema unified and capable of supporting trend determination
• □ Data return mechanism agreed with the local representative

Regulatory information verified as of 29 October 2026. The PMS requirements listed in this article follow the current text of Sections 7.2, 9.2.3(e) and 12.1(h) of EFDA-GDL-046 fourth edition and of EFDA/GDL/097 Version 002; when the guidelines are revised, the verification must be repeated.

• Local resource in Ethiopia: GRZAN assists manufacturers from the Chinese mainland and overseas in engaging the Ethiopian Food and Drug Authority (EFDA) on marketing authorisation (MA), Certificate of Competency (CoC) and import licence applications, including local representative structuring and agreement review, SRA reliance rationales, UMDN coding and classification, technical documentation, and the setup of vigilance and post-market surveillance systems.
• Service capabilities: product attribute determination and risk classification (non-IVD Class I–IV / IVD Class A–D), marketing authorisation applications and re-registration, applicability assessment for the low-risk notification procedure, Essential Principles compliance arguments, labelling and instructions-for-use localisation (English), and vigilance reporting with field safety corrective action support.
• Contact: hito.lin@grzan.cn; website www.grzan.cn.